News Pfizer snaps up PD-1/VEGF drug from China's 3SBio Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.
News Japan follows UK in GSK's comeback tour for Blenrep The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.
News Incyte's PD-1 drug brings immunotherapy to anal cancer Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer
News Pathos AI's big $365m Series D, and other bio financings Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.
News MSD adds new indication for Welireg in rare tumours MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
News AbbVie bags first approval for cancer ADC Emrelis AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
